Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibandronic acid

Drug Profile

Ibandronic acid

Alternative Names: BM 210955; Bondronat; Boniva; Bonviva; CT-064; Ibandronate; Ibandronate sodium hydrate; Methylpentylaminopropylidene; R 484; RG484; RO 2005450; Ro200-5450; Ro200-5450iv; Ro200-5450po; RPR 102289A

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche; Taisho Pharmaceutical
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Dimethylallyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer metastases; Malignant hypercalcaemia; Osteoporosis; Postmenopausal osteoporosis
  • Discontinued Cancer pain

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Sep 2016 Updated efficacy data from a phase III MOVEST trial in Oesteoporosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 23 Aug 2016 Roche withdraws a phase II trial in Cancer pain in Greece (NCT00478270)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top